Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
1(17%)
Results Posted
133%(4 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
1
17%
Ph phase_3
1
17%

Phase Distribution

4

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (66.7%)
Phase 21 (16.7%)
Phase 31 (16.7%)

Trials by Status

terminated233%
active_not_recruiting117%
completed350%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_1

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

NCT04181788
active_not_recruitingphase_3

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

NCT04165317
terminatedphase_1

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

NCT04152018
completedphase_2

Ketohexokinase Inhibition in Hereditary Fructose Intolerance

NCT06089265
terminatedphase_1

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

NCT02616185
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04181788Phase 1

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Completed
NCT04165317Phase 3

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

Active Not Recruiting
NCT04152018Phase 1

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Terminated
NCT06089265Phase 2

Ketohexokinase Inhibition in Hereditary Fructose Intolerance

Completed
NCT02616185Phase 1

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Terminated
NCT02573259Phase 1

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6